RT Journal Article
SR Electronic
T1 B cells, BAFF and interferons in MIS-C
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.18.22275245
DO 10.1101/2022.05.18.22275245
A1 Klocperk, Adam
A1 Bloomfield, Marketa
A1 Parackova, Zuzana
A1 Aillot, Ludovic
A1 Fremuth, Jiri
A1 Sasek, Lumir
A1 David, Jan
A1 Fencl, Filip
A1 Skotnicova, Aneta
A1 Rejlova, Katerina
A1 Magner, Martin
A1 Hrusak, Ondrej
A1 Sediva, Anna
YR 2022
UL http://medrxiv.org/content/early/2022/05/21/2022.05.18.22275245.abstract
AB Multisystem Inflammatory Syndrome in Children associated with COVID-19 (MIS-C) is a late complication of pediatric COVID-19, which follows weeks after original SARS-CoV-2 infection, regardless of its severity. It is characterized by hyperinflammation, neutrophilia, lymphopenia and activation of T cells with elevated IFN-γ. Observing production of autoantibodies and parallels with systemic autoimmune disorders, such as systemic lupus erythematodes (SLE), we explored B cell phenotype and serum levels of type I, II and III interferons, as well as the cytokines BAFF and APRIL in a cohort of MIS-C patients and healthy children after COVID-19.We documented a significant elevation of IFN-γ, but not IFN-α and IFN-λ in MIS-C patients. BAFF was elevated in MIS-C patient sera and accompanied by decreased BAFFR expression on all B cell subtypes. The proportion of plasmablasts was significantly lower in patients compared to healthy post-COVID children. We noted the presence of ENA Ro60 autoantibodies in 4/35 tested MIS-C patients.Our work shows the involvement of humoral immunity in MIS-C and hints at parallels with the pathophysiology of SLE, with autoreactive B cells driven towards autoantibody production by elevated BAFF.Summary sentence Elevated serum BAFF in children with MIS-C supports the state of polyclonal B cell activation and autoimmune phenomena characterizing this disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work was supported by AZV NU20-05-00320 and NU20-05-00282 issued by the Czech Health Research Council and Ministry of Health, Czech Republic and institutional support of research organization #00064203 from University Hospital in Motol, Czech Republic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethical Committee of the University Hospital in Motol, reference no. EK-1376/21.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.